Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 1, 2018-01 ,pp. : 20-29

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors Affecting the Tuberculosis Risk in Patients Receiving Anti-Tumor Necrosis Factor-α Treatment

By  

Respiration, Vol. 90, Iss. 3, 2015-0 ,pp. : 191-198

Karger

Access to resources Recommend Favorite

Quality of life restoration in Crohn's disease

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 2, 2015-02 ,pp. : 286-291

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

By Sandborn W. J.   Colombel J.-F.   D’Haens G.   Plevy S. E.   Panés J.   Robinson A. M.   Pollack P. F.   Zhou Q.   Castillo M.   Thakkar R. B.  

Current Medical Research and Opinion, Vol. 29, Iss. 5, 2013-05 ,pp. : 483-493

Informa Healthcare

Access to resources Recommend Favorite

The risk of tuberculosis in patients with psoriasis treated with anti‐tumor necrosis factor agents

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : 594-599

John Wiley & Sons Inc

Access to resources Recommend Favorite